Dreadful Stocks to Avoid

Warren Buffett's first rule of investing is: "Never lose money." To this, he often adds rule No. 2: "Never forget rule No. 1." Of course, following these rules is easier said than done. But Buffett's done pretty well, so it seems unwise to simply dismiss his advice as the semi-coherent ramblings of a man who's read way too many 10-Ks.

I take those rules to heart in my investment strategy. I try to focus my investment dollars on sustainable, undervalued businesses that I can easily understand. Buffett has made more than $40 billion for himself using that strategy, and he's made even more for his partners and shareholders over the years.

Do you really need to assume a lot of risk to make more than $40 billion? My answer, and the answer of my colleagues at Motley Fool Inside Value, is "Heck, no!" If I make only $40 billion, I'll be perfectly satisfied.

People spend a lot of time discussing the companies Buffett buys. But in the spirit of not losing money, it's equally worthwhile to understand the types of businesses that Buffett does not buy in order to steer clear of potential duds. I see five main categories:

1. Businesses that bet the farm
In some industries, companies occasionally have to make critically important decisions. If the company makes the wrong choice, it will be dealt a crippling blow. This is terrible for a shareholder, because even if the company makes the right decision one month, it might fail to do so the next. There's no "three strikes and you're out" policy. One strike, and it's game over -- your money's gone.

2. Businesses dependent on research
It's quite reasonable to believe that research can be a competitive advantage for certain companies. In fact, one reason Gilead Sciences (Nasdaq: GILD  ) has been so successful is that it has devoted so much to top-notch research and development. Nevertheless, there is a downside to research. Often, innovative companies are required to do research simply to maintain their competitive position. And if the research dries up, the company suffers.

For instance, consider the plight of Schering-Plough (NYSE: SGP  ) . Like many of the huge pharma companies, Schering-Plough had a long and impressive history of earnings growth because of new breakthrough products and a promising pipeline. But in the past five years, Schering has been unimpressive. The company has seen various problems within its pipeline, costs are adding up, and Vytorin -- once its most promising blockbuster -- now faces a very uncertain future.

This is in stark contrast to a company like Diageo (NYSE: DEO  ) , which could develop nothing for a decade and still have a very healthy business. While I don't think this is sufficient reason to sell off all your tech or biotech stocks, I can understand why Buffett avoids such investments.

3. Debt-burdened companies
In general, Buffett avoids companies with a lot of debt. This makes sense. During the best of times, large amounts of debt mean that cash that could be put toward growing the business or rewarding shareholders is instead servicing the debt. In a crisis, debt greatly limits a company's options and can sometimes lead to bankruptcy.

A more subtle point is that great businesses throw off piles of cash. Great businesses generally don't need to use huge amounts of debt leverage to achieve an acceptable return for shareholders. So, if a company needs debt to achieve reasonable returns, it's less likely to be a great business.

You can see this with Pulte Homes (NYSE: PHM  ) and DR Horton (NYSE: DHI  ) . Both have billions of dollars in debt at levels that far exceed their respective cash positions. More importantly, they rely on this debt to build out their productive capacities -- it’s a necessity. Now that they’re in a horrible housing environment, the two must pay back that money while trying to compete in a miserable competitive landscape. It’s a brutal combination.

4. Companies with questionable management
Management has incredible power. If executives want to enrich themselves at the expense of shareholders, either directly or by misrepresenting the company's prospects, individual shareholders have almost no hope of stopping them. I strongly recommend avoiding companies where there's even a hint that management lacks integrity.

Some clues to look for here include excessively optimistic press releases, overly generous compensation or options grants, and frequently blaming external circumstances for operational shortcomings. WorldCom and Enron shares may have risen for years, but at the end of the day, shareholders received almost nothing. That's why I think questionable management is the worst flaw a company can have.

5. Companies that require continued capital investment
Over the long term, shareholders make spectacular returns by buying businesses that are able to achieve extraordinary returns on capital. This leads to excess capital that the company can use to repurchase shares, pay a dividend to shareholders, or reinvest in further growth.

Companies that constantly need to make additional capital investment to keep the business going are the antithesis of this ideal -- the main beneficiaries will be employees, management, suppliers, and government. Take a look at Coeur d’Alene (NYSE: CDE  ) and its long-term performance to substantiate this point.  In other words, everyone profits except shareholders.

The upshot
These characteristics don't necessarily make a company a bad investment.Genentech (NYSE: DNA  ) , for instance, has been a great long-term investment despite ongoing R&D and capital expenditures. But a solid understanding of why these types of companies may be undesirable can help you identify whether a company that looks good on the surface might actually cost you money later.

We use similar techniques at Motley Fool Inside Value. With every stock, we cautiously evaluate each of these factors -- focusing on competitive advantages, potential threats, the balance sheet, and anything we can glean from SEC filings -- to determine whether the business is likely to provide a solid return for shareholders in the future. In our initial recommendation of any company, we discuss the risks the company faces and provide updates when new risks appear on the horizon.

By focusing on great businesses and understanding the potential risks of any company, we endeavor to achieve Buffett's first rule -- "Never lose money." To see the companies we've identified, take a 30-day guest pass to Inside Value. There's no obligation to subscribe.

Already subscribe to Inside Value? Log in at the top of this page.

This article was originally published on Oct. 7, 2005. It has been updated.

Fool contributor Richard Gibbons has forgotten what rule No. 2 is. He does not have a position in any of the companies mentioned in this article. Diageo is a Motley Fool Income Investor pick. The Motley Fool has a disclosure policy.


Read/Post Comments (6) | Recommend This Article (7)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 25, 2009, at 4:58 PM, paultaut wrote:

    Do me a Favor, short CDE. I will enjoy watching the scramble to cover.

  • Report this Comment On July 26, 2009, at 12:13 PM, RainierMan wrote:

    Oh, but, oops, SGP has been a fine stock as of late. But why let facts get in the way of an idea for an article.

  • Report this Comment On July 26, 2009, at 11:07 PM, artisan99 wrote:

    Biotechs have a long development cycle so it is often not good to get in too early so when do you get in? I have watched and own several which have not paid off yet. One example is GNBT. Their drug RI-78 is 4000 time more powerful than morphine and none of the side effects. There are others in the pipeline or just coming on the market. But then, I call myself an investor. If we all did like Buffet, there would be a lot of furniture stores and no biotech.

  • Report this Comment On July 27, 2009, at 7:10 AM, andywd82 wrote:

    CDE got killed because precious metals got killed. If precious metals catch fire, so will CDE. And last time I checked, precious metals were on the up (as is CDE).

    Better "value" than 90% of the other stuff out there IMHO.

  • Report this Comment On July 28, 2009, at 10:50 AM, artisan99 wrote:

    I need to make a correction to my previous comment. I confused two stocks that I owned. The company that has the pain drug, which is RPI-78 is NutraPharma ( NPHC.OB ). Sorry for the error.

  • Report this Comment On December 31, 2011, at 10:15 AM, BetrayedbyGovt wrote:

    What about the rumor of pfizer buy out of Nutra Pharma Corp (NPHC.OB) $5 to $7 per share. Sound cheap to me. Many great patents and applications.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 950173, ~/Articles/ArticleHandler.aspx, 10/26/2014 1:13:17 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement